Parnell restructures board; Jaguar completes second Neonorm study; Novozymes forges into animal probiotics;

> Parnell Pharmaceuticals ($PARN) announced that three members of its board of directors have resigned and that the company has hired the executive search firm Egon Zehnder to recruit independent directors with expertise in animal health. Release

> Jaguar Animal Health ($JAGX) announced it has completed a second field study of Neonorm Calf that showed a beneficial effect on prewean weight gain and normalization of digestion. Release

> Novozymes acquired Fayetteville, Arkansas-based Pacific Vet Group-USA, a maker of probiotics for animals, for an undisclosed sum. Release

> PetCure Oncology has formed a scientific advisory board consisting of 10 experts in veterinary radiation oncology, medical oncology, stereotactic radiosurgery and medical physics. Release

> Integrated Animal Health announced it has initiated field trials for two products that reduce the risk of scours in calves. Release

> The Animal Medical Center of New York City has unveiled its new Cancer Institute, a 2,470-square-foot facility with a staff of 22, including four veterinary oncologists. Release

> K-9 Kraving Dog Food has recalled some lots of its Chicken Patties Dog Food because of potential contamination with Salmonella and Listeria monocytogenes. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…